Crescita Therapeutics (CTX) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue declined 21% year-over-year to $4.1M, with gross profit down 27% to $2.2M and an adjusted EBITDA loss of $0.7M compared to a $0.2M gain in Q2 2023.

• Net loss widened to $0.9M ($0.05/share) from $0.3M ($0.01/share) in Q2 2023, driven by lower manufacturing revenue and gross margin compression.

• Cash balance at quarter-end was $9.0M, with working capital of $12.0M and no debt drawn on a $3.5M credit facility.

• Strategic initiatives included a manufacturing agreement amendment, a new supply deal with a Canadian healthcare provider, a distribution agreement for MicronJet, and the acquisition of Occy Laboratoire assets.

Financial highlights

• Q2 2024 revenue: $4.1M (down from $5.2M in Q2 2023); gross margin: 54.7% (down from 59.5%).

• Adjusted EBITDA: $(0.7)M vs. $0.2M in Q2 2023; net loss: $(0.9)M vs. $(0.3)M.

• Cash used in investing activities: $0.9M, mainly for the Occy asset acquisition.

• Cash provided by operations: $0.5M, up from $0.1M in Q2 2023 due to favorable working capital movements.

• Ending cash: $9.0M; total assets: $23.0M; total equity: $17.2M.

Outlook and guidance

• Management expects sufficient liquidity to fund operations and execute its growth strategy, with a focus on organic growth, strategic acquisitions, and contract manufacturing.

• Revenue growth and profitability depend on successful execution of new agreements and market acceptance of products.